JATT II Acquisition Corp. JATT
10.38 USD -0.10 (-0.95%)
At closeNov 12, 2026, 4:00 PM EST
10.27 -0.11 -1.01%
After hours · Nov 12, 4:00 PM ET
10.25 Day range 10.45
9.99 52-week range 23.76
- YTD
- -1.19%
- 1 year
- -1.19%
News
benzinga.com JATT II Acquisition To Merge With Talawar Therapeutics; Combined Company Expects To Receive $285M In PIPE Financing Upon Closing Oversubscribed $225 million concurrent private investment in public equity ("PIPE") with available cash to the combined company at closing anticipated to fund TALA-125 through a Phase 2b…
benzinga.com JATT Acquisition Corp Announces Planned Transfer Of Listing To NASDAQ In Connection With Its Proposed Business Combination With Zura Bio Limited JATT Acquisition Corp (NYSE:JATT, JATT.WS and JATT.U)))) (the "Company"), a publicly-traded special purpose acquisition company, today announced that it will voluntarily transfer the listing of its…
benzinga.com With The Execution Of The License Agreement, For Lilly Entering Into The License Agreement With Z33, JATT And Lilly Entered Into That Certain Equity Grant Agreement, Pursuant To Which JATT Agreed To Issue And Grant To Lilly 550K Class A Ordinary Shares In A Private Placement Transaction Concurrently with the execution of the License Agreement, on December 8, 2022, as partial consideration for Lilly entering into the License Agreement with Z33, JATT and Lilly entered into that…- benzinga.com On December 8, 2022, Z33 Bio Inc. An Entity Controlled By Zura Entered Into The License, Development And Commercialization Agreement With Eli Lilly And Company As previously announced on June 16, 2022, JATT Acquisition Corp, a Cayman Islands exempted company (“JATT” or the “SPAC”) entered into a Business Combination Agreement (as it may be amended,
- benzinga.com JATT Acquisition Corp. And Zura Bio Announce Business Combination; Transaction Values The Combined Companies At A Pro Forma Enterprise Value Of $215M Company advancing ZB-168, an anti-IL7Rα monoclonal antibody, originally developed by Pfizer Inc., in multiple phase 2 clinical trials The transaction values the combined companies at a pro forma…